Acambis competitor seeks to block shipments of smallpox vaccine to U.S.

08/22/2005 | Guardian (London), The

The only two companies that produce a weakened smallpox vaccine for preventing the disease in the elderly and people with weakened immune systems are competing for a U.S. contract worth $1.9 billion, and are doing battle in court for the contract. Bavarian Nordic, a Swedish biotech, has a lawsuit pending in the U.S. against Acambis, alleging Acambis developed its MVA vaccine with BV's research information and technology, amounting to "misappropriation of trade secrets," and seeks to stop Acambis from exporting its vaccine to the U.S.

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC